The role of human papillomavirus infection in prostate cancer

Saudi Medical Journal

Volumn 28, Issue 3, 2007, Pages 326-333

  Al Maghrabi, Jaudah A ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER STAGING; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CONDYLOMA; DISEASE ASSOCIATION; GENITAL TRACT CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; SAUDI ARABIA; SEXUALLY TRANSMITTED DISEASE; SOUTHERN BLOTTING; TELOMERE; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WESTERN BLOTTING;

AGE DISTRIBUTION; AGED; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SAUDI ARABIA; TUMOR VIRUS INFECTIONS;

EID: 34247217585     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Eversole LR. Papillary lesions of the oral cavity: relationship to human papillomaviruses. J Calif Dent Assoc 2000; 28: 922-927.
2. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78:11451-11460.
3. Herrero R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996; 21: 1-6.
4. Munoz N, Bosch FX. Epidemiology of cervical cancer. IARC Sci Publ 1989; 94: 9-39.
5. Orth G, Favre M. Human papillomaviruses. Biochemical and biologic properties. Clin Dermatol 1985; 3: 27-42.
6. de Villiers EM, Gissmann L, zur HH. Molecular cloning of viral DNA from human genital warts. J Virol 1981; 40: 932-935.
7. Garza ML, Chandhasin C, Ducu RI, Marriott SJ. Impact of transforming viruses on cellular mutagenesis, genome stability, and cellular transformation. Environ Mol Mutagen 2005; 45: 304-325.
8. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002; 40: 886-891.
9. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-372.
10. Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Stanley M, et al. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer 2004; 91: 2063-2070.
11. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208: 152-164.
12. Duensing S, Lee LY, Duensing A. Basile J, Piboonniyom S, Gonzalez S, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci U S A 2000; 97: 10002-10007.
13. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A 2000; 97: 6693-6697.
14. Griffiths TR, Mellon JK. Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer. BJU Int 2000; 85: 211-217.
15. Yu ST, Wu MM, Li LM. Prevalence of human papillomaviruses 16 and 18 in transitional cell carcinoma of bladder. Chin Med J (Engl) 1993; 106: 494-496
16. Akgul B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006; 208: 165-175.
17. El-Mofty SK, Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 339-345.
18. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K. Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: Review of the literature of human papillomavirus detection in these carcinomas. Pathol Int 2006; 56: 301-308.
19. Brawley OW, Knopf K, Thompson I. The epidemiology of prostate cancer part II: the risk factors. Semin Urol Oncol 1998; 16: 193-201.
20. Fournier G, Valeri A. Mangin P, Cussenot O. [Prostate cancer. Epidemiology. Risk Ectors. Pathology]. Ann Urol (Paris) 2004; 38: 187-206.
21. Iwasaki M, Tsugane S. [Risk factors and current chemoprevention studies in prostate cancer]. Nippon Rinsho 2005; 63: 321-326.
22. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Loblaw A, et al. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. Can J Urol 2006; 13 Suppl 2: 2-10.
23. Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, Thoresen S, et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005; 14: 2952-2955.
24. Peehl DM, Sellers RG, Arnstein P, Kung HF, Rhim JS. Altered growth regulation and loss of response to retinoic acid accompany tumorigenic transformation of prostatic cells. Anticancer Res 1999; 19 (5B): 3857-3864.
25. Anderson M, Handley J, Hopwood L, Murant S, Stower M, Maitland NJ. Analysis of prostate tissue DNA for the presence of human papillomavirus by polymerase chain reaction, cloning, and automated sequencing. J Med Virol 1997; 52: 8-13.
26. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinoma. Cancer Res 1992; 52: 5991-5996.
27. Cuzick J. Human papillomavirus infection of the prostate. Cancer Surv 1995; 23: 91-95.
28. Dillner J, Knekt P, Boman J, Lehtinen M, Af Geijersstam V, Sapp M, et al. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998; 75: 564-567.
29. Dodd JG, Paraskevas M, McNicol PJ. Detection of human papillomavirus 16 transcription in human prostate tissue. J Urol 1993; 149: 400-402.
30. Effert PJ, Frye RA, Neubauer A, Liu ET, Walther PJ. Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 1992; 147: 192-196.
31. Hisada M, Rabkin CS, Strickler HD, Wright WE, Christianson RE, van den Berg BJ. Human papillomavirus antibody and risk of prostate cancer [letter]. JAMA 2000; 283: 340-341.
32. McNicol PJ, Dodd JG. Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol 1990; 28: 409-412.
33. McNicol PJ, Dodd JG. Detection of papillomavirus DNA in human prostatic tissue by Southern blot analysis. Can J Microbiol 1990; 36: 359-362.
34. McNicol PJ, Dodd JG. High prevalence of human papillomavirus in prostate tissues. J Urol 1991; 145: 850-853.
35. Moyret-Lalle C, Marcais C, Jacquemier J, Moles JP, Daver A, Soret JY, et al. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995; 64: 124-129.
36. Rotola A. Monini P, Di Luca D, Savioli A, Simone R, Secchiero P, et al. Presence and physical state of HPV DNA in prostate and urinary-tract tissues. Int J Cancer 1992; 52: 359-365.
37. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999; 20: 22-45.
38. Strickler HD, Schiffman MH, Shah KV, Rabkin CS, Schiller JT, Wacholder S, et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998; 7: 305-313.
39. Strickler HD, Burk R, Shah K, Viscidi R, Jackson A, Pizza G, et al. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998; 82: 1118-1125.
40. Suzuki H, Komiya A, Aida S, Ito H, Yatani R, Shimazaki J. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 1996; 28: 318-324.
41. Terris MK, Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology 1997; 50: 150-156.
42. Tu H, Jacobs SC, Mergner WJ, Kyprianou N. Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology 1994; 44: 726-731.
43. Wideroff L, Schottenfeld D, Carey TE, Beals T, Fu G, Sakr W, et al. Human papillomavirus DNA in malignant and hyperplastic prostate tissue of black and white males. Prostate 1996; 28: 117-123.
44. Ibrahim GK, Gravitt PE, Dittrich KL, Ibrahim SN, Melhus O, Anderson SM, et al. Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization. J Urol 1992; 148: 1822-1826.
45. Sarkar FH, Sakr WA, Li YW, Sreepathi P, Crissman JD. Detection of human papillomavinis (HPV) DNA in human prostatic tissues by polymerase chain reaction (PCR). Prostate 1993; 22: 171-180.
46. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999; 59: 823-825.
47. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinoma of patients from Argentina. BMC Urol 2005; 5: 15.
48. Taylor ML, Mainous AG, III, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005; 37: 506-512.
49. Strickler HD, Burk R, Shah K, Viscidi R, Jackson A, Pizza G, et al. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998; 82: 1118-1125.
50. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999; 59: 823-825.
51. Tu H, Jacobs SC, Mergner WJ, Xyprianou N. Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology 1994; 44: 726-731.
52. Terris MK, Peehl DM. Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology 1997; 50: 150-156.
53. Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2003; 12: 872-875.
54. Dillner J, Knekt P, Boman J, Lehtinen M, Af Geijersstam V, Sapp M, et al. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998; 75: 564-567.
55. Elhakeem HA, Al-Ghamdi AS, Al-Maghrabi JA. Cytopathological pattern of cervical Pap smear according to the Bethesda system in Southwestern Saudi Arabia. Saudi Med J 2005; 26: 588-592.
56. Jamal A. Al-Maghrabi JA. Profile of Pap smear cytology in the Western region of Saudi Arabia. Saudi Med J 2003; 24: 1225-1229.
57. Abomelha MS. Genito-urinary cancer in Saudi Arabia. Saudi Med J 2004; 25: 552-556.
58. Hanash KA, Al-Othaimeen A, Kattan S, Lindstedt E, Al-Zahrani H, Merdad T, et al. Prostatic carcinoma: a nutritional disease? Confficting data from the Kingdom of Saudi Arabia. J Urol 2000; 164: 1570-1572.
59. Mosli HA. Prostate cancer in Saudi Arabia in 2002. Saudi Med J 2003; 24: 573-581.
60. Taha SA, Kamal BA. Screening program for prostate cancer at a university hospital in eastern Saudi Arabia. Saudi Med J 2005; 26: 1104-1106.
61. Al-Maghrabi J, Vorobyova L, Chapman W, Jewett M, Zielenska M, Squire JA. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 2001; 14: 1252-1262.
62. Al-Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA. Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med 2002; 126: 165-169.
63. Al-Maghrabi JA. Chromosomal instability detected by interphase fluorescence in situ hybridization and its relation to p53 alteration in prostate carcinoma in Saudi patients. Saudi Med J 2005; 26: 379-384.
64. Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A. et al. Evidence of multifixality of telomere erosion in high-grade prostatic inn-aepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 2003; 22: 1978-1987.
65. al-Ahdal MN, Kardar AH, Selim AM, Kessie G. Occurrence of human papillomavirus types 16 and 18 in benign prostatic hyperplasia tissues of Saudi patients. Genitourin Med 1996; 72: 345-346.
66. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinoma. Cancer Res 1992; 52: 5991-5996.
67. Rosenblatt KA, Carter JJ, Iwasaki IM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 763-768.
68. Duensing S, Munger K. Centrosome abnormalities and genomic instability induced by human papillomavirus oncoproteins. Prog Cell Cycle Res 2003; 5: 383-391.
69. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002; 62: 7075-7082.
70. Duensing S, Duensing A, Crum CP, Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 2001; 61: 2356-2360.
71. Thomas JT, Laimins LA. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol 1998; 72: 1131-1137.
72. Fan X, Chen JJ. Regulation of cell cycle progression and apoptosis by the papillomavirus E6 oncogene. Crit Rev Eukaryot Gene Expr 2004; 14: 183-202.
73. Ruijter E, van de Kaa C, Aalders T, Ruiter D, Miller G, Debruyne F, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11: 276-281.
74. Salem CE, Tomasic NA, Elmajian DA, Esrig D, Nichols PW, Taylor CR, et al. p53 protein and gene alterations in pathological stage C prostate carcinoma [see comments]. J Urol 1997; 158: 510-514.
75. Schlechte HH, Schnorr D, Loning T, Rudolph BD, Pohrt UM, Loening SA. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers-investigation by temperature gradient gel electrophoresis (TGGE). J Urol 1997; 157: 1049-1053.
76. Stattin P, Bergh A. Karlberg L, Nordgren H, Damber JE. p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur Urol 1996; 30: 65-72.
77. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996; 2: 399-401.
78. Yasunaga Y, Shin M, Fujita MQ, Nonomura N, Miki T, Okuyama A, et al. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens. Lab Invest 1998; 78: 1275-1279.
79. zur HH. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-F78.
80. Vecchione A, Cermele C, Giovagnoli MR, Valli C, Alimandi M, Carico E, et al. p53 expression and genetic evidence for vital infection in intraepithelial neoplasia of the uterine cervix. Gynecol Oncol 1994; 55(3 Pt 1): 343-348.
81. Pihan GA, Purohit A. Wallace J, Knecht H, Woda B, Quesenberry P, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998; 58: 3974-3985.
82. Seckinger D, Sugarbaker E, Frankfurt O. DNA content in human cancer. Application in pathology and clinical medicine. Arch Pathol Lab Med 1989; 113: 619-626.
83. Barlogie B, Drewinko B, Schumann J, Gohde W, Dosik G, Latreille J, et al. Cellular DNA content as a marker of neoplasia in man. Am J Med 1980; 69: 195-203.
84. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-627.
85. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
86. Hartwell L, Weinert T, Kadyk L, Garvik B. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harb Symp Quant Biol 1994; 59: 259-263.
87. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
88. Rudner AD, Murray AW. The spindle assembly checkpoint. Curr Opin Cell Biol 1996; 8: 773-780.
89. Wells WA, Murray AW. Aberrantly segregating centromeres activate the spindle assembly checkpoint in budding yeast. J Cell Biol 1996; 133: 75-84.
90. Mazia D. The chromosome cycle and the centrosome cycle in the mitotic cycle. Int Rev Cytol 1987, 100: 49-92.
91. Merdes A. Cleveland DW. Pathways of spindle pole formation: different mechanisms; conserved components. J Cell Biol 1997; 138: 953-956.
92. Fukasawa K, Choi T, Kuriyama R, Rutong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996; 271: 1744-1747.
93. Kellogg DR, Moritz M, Alberts BM. The centrosome and cellular organization. Annu Rev Biochem 1994; 63: 639-674.
94. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995; 55: 5408-5414.
95. Qian J, Bostwick DG. The extent and zonal location of prostatic intraepithelial neoplasta and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract 1995; 191: 860-867.
96. Bergerheim US, Kunimi K, Collins VP, Ekman P. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 1991; 3: 215-220.
97. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998; 83: 1995-2002.
98. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995; 55: 2959-2962.
99. Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chromosomes Cancer 1993; 8: 88-97.
100. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994; 54: 3273-3277.
101. 1 Hittelman WN. Genetic instability in epithelial tissues at risk for cancer. Ann N Y Acad Sci 2001; 952: 1-12.
102. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-162.
103. Malek RS, Goellner JR, Smith TF, Espy MJ, Cupp MR. Human papillornavirus infection and intraepithelial, in situ, and invasive carcinoma of penis. Urology 1993; 42: 159-170.
104. Sen S, Reddy VG, Guleria R, Jain SK, Kapila K, Singh N. Telomerase - a potential molecular marker of lung and cervical cancer. Clin Chem Lab Med 2002; 40: 994-1001.
105. Stoppler H, Hartmann DP, Sherman L, Schlegel R. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length. J Biol Chem 1997; 272: 13332-13337.
106. Serfling U, Ciancio G, Zhu WY, Leonardi C, Penneys NS. Human papillomavirus and herpes virus DNA are not detected in benign and malignant prostatic tissue using the polymerase chain reaction. J Urol 1992, 148: 192-194.
107. Gherdovich S, Barbacci P, Mitrione MP, Farina U, Muraro GB, Anichini M. [Detection of the human papillomavirus in hyperplastic and cancerous prostatic: tissue with PCR]. Minerva Urol Nefrol 1997; 49: 73-77.
108. Noda T, Sasagawa T, Dong Y, Fuse H, Namiki M, Inoue M. Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res 1998; 26: 165-169.
109. Saad F, Gu K, Jean-Baptiste J, Gauthier J, MesMasson AM. Absence of human papillomavirus sequences in early stage prostate cancer. Can J Urol 1999; 6: 834-838.
110. Carozzi F, Lombardi FC, Zendron P, Confortini M, Sani C, Bisanzi S, et al. Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int J Biol Markers 2004; 19: 257-261.